Prise en charge individualisée des patients atteints de DMLA exsudative, le protocole IOI : injection–observation–individualisation

International audienceWet macular degeneration remains a major cause of visual impairment in people over 55years. Through a group of experts belonging to the Federation France Macula, we review the treatment of wet AMD and provide recommendation with a 3 phases protocol called IO

Ranibizumab in patients with neovascular age-related macular degeneration in real-world clinical settings in France: 1-year data from the LUMINOUS (TM) study

International audienc